期刊
TRANSPLANTATION
卷 102, 期 2, 页码 S44-S46出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0000000000001693
关键词
-
资金
- Fund for Scientific Research (FWO)-Flanders [G.0160.13N, G.0412.16N]
- University of Antwerp (BOF)
Inhibitors of the mechanistic target of rapamycin (mTOR) have unique antiatherosclerotic effects, such as depletion of plaque macrophages, induction of autophagy, and activation of cholesterol efflux. However, a common side effect of their use is dyslipidemia, a well-known risk factor for atherosclerosis. Indeed, mTOR inhibitors prevent lipid storage, increase low-density lipoprotein cholesterol levels, and activate lipolysis. Although the net effect of mTOR inhibition seems favorable, the use of cholesterol lowering drugs to manage dyslipidemia remains the most recommended strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据